In this review:
Bisphosphonate drug holidays and hip fracture rates
Bimekizumab in patients with active ankylosing spondylitis
Baricitinib in systemic lupus erythematosus
ANA development & response to bDMARDs in RA
Mycophenolate mofetil for scleroderma-related ILD
Does adalimumab withdrawal in NR-AXSPA increase risk of flare?
Osteoporotic hip fractures in men: a rising concern
Geolocation impacts severity of primary Sjögren syndrome
Rituximab for induction and maintenance of AAV disease
Management of asymptomatic antiphospholipid antibody carriers
Please login below to download this issue (PDF)